Intervention not reported
Severe adverse events: serum glutamic‐ pyruvic transaminase (SGPT) · antiretroviral‐naïve individuals
1 finding from 1 review
Intervention not reported
Raised cholesterol · antiretroviral‐naïve individuals
The intervention showed no clear difference in raised cholesterol (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality · antiretroviral‐naïve individuals
The intervention showed no clear difference in mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression to AIDS · antiretroviral‐naïve individuals
The intervention showed no clear difference in progression to AIDS (moderate certainty).
1 finding from 1 review
Intervention not reported
All severe adverse events · antiretroviral‐naïve individuals
It is very uncertain whether the intervention changes all severe adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Discontinuation rate · antiretroviral‐naïve individuals
The intervention showed no clear difference in discontinuation rate (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in CD4 count · antiretroviral‐naïve individuals
1 finding from 1 review
Intervention not reported
Treatment failure · antiretroviral‐naïve individuals
The intervention showed no clear difference in treatment failure (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: central nervous system · antiretroviral‐naïve individuals
The intervention probably leads to higher severe adverse events: central nervous system (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: gastrointestinal · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: gastrointestinal (low certainty).
1 finding from 1 review
Intervention not reported
Treatment failure · treating pulmonary TB
The intervention showed no clear difference in treatment failure (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse · treating pulmonary TB
The intervention showed no clear difference in relapse (low certainty).
1 finding from 1 review
Intervention not reported
Death · treating pulmonary TB
The intervention showed no clear difference in death (moderate certainty).
1 finding from 1 review
Intervention not reported
Sputum smear or culture conversion at end of treatment · treating pulmonary TB
The intervention showed no clear difference in sputum smear or culture conversion at end of treatment (high certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · treating pulmonary TB
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events leading to discontinuation of therapy · treating pulmonary TB
The intervention showed no clear difference in adverse events leading to discontinuation of therapy (low certainty).
1 finding from 1 review
Intervention not reported
Combined endpoint of treatment failure, relapse, or death** · treating pulmonary TB
1 finding from 1 review
Remaining parasitaemic at 24 hours · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT leads to lower remaining parasitaemic at 24 hours compared with CQ (high certainty).
1 finding from 1 review
Remaining febrile after 24 hours · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT probably leads to lower remaining febrile after 24 hours compared with CQ (moderate certainty).
1 finding from 1 review
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in effective treatment of the blood stage parasite As assessed by:… compared with CQ (high certainty).
1 finding from 1 review